Muco-trapping antibodies for protection and treatment of mucosal infections
|AFFILIATION:||Mucommune, LLC, Chapel Hill, North Carolina, United States|
Track: Medical & Biotech
Area: Infectious Disease
Tech Readiness: TRL 3
Tech Brief: Mucommune's core technology is antibodies that trap pathogens in mucus, thereby enabling protection directly at portal of entry. The technology is broadly applicable to viral and bacterial pathogens at different mucosal surfaces, with successful in vivo proof-of-concept and one STTR contract from NIAID to date.
Value Proposition: Infectious disease is not only a bioterrorist threat but a major challenge to national security in light of increasing emergence of infections with no existing prevention or treatment options (e.g. Zika, Ebola). The duration it takes to develop vaccines (1-2 years +) are inadequate for rapid response, and vaccines remain extremely challenging for most mucosal infections. For example, with exception of HPV and HBV, we have no vaccine against all common STIs including HIV, HSV, Chlamydia, Gonnorhea, etc. In contrast, screening and production of pathogen-specific antibodies can be readily achieved in months, and protective doses can be readily administered to personnel at highest risks of acquiring infections (e.g. soldiers, medical personnel). Combined with rapidly reducing costs of antibody production, topical immunoprophylaxis and immunotherapy against emerging pathogens represents a powerful arsenal that should be part of any national defense. Mucommune's technology specifically enhances antibody protection at mucosal surfaces where most infections are transmitted.
Org Type: Early-stage Startup (Seed)
Booth Number: W613